First report of myocarditis in two patients with COVID-19 Omicron variant: case report

Boris Fishman *,†, Orly Goitein †, Anat Berkovitch, Galia Rahav *, and Shlomi Matetzky

Sheba Medical Center, Tel Hashomer, affiliated to Sackler Medical School, Tel Aviv University, Israel

Received 30 January 2022; first decision 14 June 2022; accepted 4 October 2022; online publish-ahead-of-print 5 October 2022

Background
Severe acute respiratory syndrome coronavirus 2 infection is responsible for the coronavirus disease 2019 (COVID-19) pandemics. Omicron (B.1.1.529) variant is the cause for the surge of the COVID-19 pandemics of the end of 2021 and the beginning of 2022, although its subvariants are responsible for the following daily increase of COVID-19 cases in July 2022. Early reports of Omicron variant confirmed patients indicated less severe disease course compared with the disease caused by previously encountered variants with absence of data regarding cardiac involvement by Omicron.

Case summary
A 42-year-old male who tested positive for Omicron was admitted on January 2022 with chest pain and ST-segment elevation in the inferior leads. Coronary angiography revealed non-significant coronary artery disease. Cardiac magnetic resonance imaging demonstrated features consistent with myocarditis with involvement of 22% of the left ventricular mass by late gadolinium enhancement involving both the lateral and the septal walls. The second patient is a 60-year-old male presented following syncope and palpitations after he was confirmed with Omicron infection. Upon emergency department arrival he had ventricular tachycardia of 250 beats/minute and underwent urgent cardioversion. During his hospitalization, there was no recurrence of malignant arrhythmia, coronary angiography revealed non-obstructive disease. Cardiac magnetic resonance imaging demonstrated imaging features suggesting acute myocarditis with involvement of 19% of the left ventricular mass.

Discussion
This is the first report of myocarditis cases as a possible complication associated with Omicron variant. Despite preliminary reports of less severe disease clinicians should be vigilant for potential deleterious cardiac complications of Omicron.

Keywords
COVID-19 • Omicron • Myocarditis • Case report

ESC Curriculum
2.3 Cardiac magnetic resonance • 5.6 Ventricular arrhythmia

Learning points
- Coronavirus disease 2019 (COVID-19) pandemic is on the rise due to the recently recognized Omicron (B.1.1.529) variant which is suggested by preliminary reports to cause less severe disease compared to previous variants.
- Omicron may cause myocarditis with consequent malignant arrhythmias similar to previously encountered SARS-CoV2 variants.
- Cardiac magnetic resonance imaging may be helpful in the diagnosis of myocarditis in the setting of COVID-19 caused by the Omicron.
Introduction
The coronavirus disease 2019 (COVID-19) pandemic has been a major public health issue for the last 2 years, accounting for more than 300 million confirmed cases, causing over 5.5 million deaths. The first four major SARS-CoV2 variants were Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.617.2). They resulted in waves of pandemic and multigang involvement with severe lower respiratory tract involvement as the leading determinant of fatality. Although myocardial injury is common among patients with COVID-19, with up to 57% in some cohorts, the incidence of frank clinical myocarditis is probably much lower. Yet, these myocarditis cases are clinically important with potential deleterious effects including fulminant myocarditis with clinical deterioration to heart failure and death. By November 2021, Omicron (B.1.1.529) is designated as the fifth major variant and from December 2021 it has become the dominant variant in many countries worldwide. Omicron’s subvariants (such as the BA.1 and BA.2) are responsible for the increase in daily COVID-19 cases reported in June and July 2021. Preliminary reports from South Africa report of different, more subtle clinical course of Omicron variant. There is scarce data regarding Omicron’s cardiac involvement, here we report for the first time two cases of myocarditis in acutely infected Omicron patient.

Timeline patient 1:

| Date         | Significant event                                                                                                                                 |
|--------------|-------------------------------------------------------------------------------------------------------------------------------------------------|
| 8.1.2022     | The patient presented to the emergency department (ED) with squeezing chest pain, ST elevation in the inferior leads of 12 lead ECG, elevated level of troponin I and inferior wall motion hypokinesis on echocardiography |
| 8.1.2022     | Urgent coronary angiography was performed, showing non-significant coronary artery disease                                                                                                                   |
| 8.1.2022     | A nasopharyngeal swab was for SARS-CoV-2 on real-time reverse transcriptase–polymerase chain reaction (PCR) assay                                                                                          |
| 9.1.2022     | The Omicron variant was confirmed by genotyping                                                                                                                                                        |
| 11.1.2022    | Cardiac magnetic resonance imaging (MRI) demonstrated imaging features consistent with acute myocarditis with involvement of 22% of the left ventricular mass by late gadolinium enhancement |
| 13.1.2022    | The patient was discharged from the hospital after being treated with ibuprofen and colchicine with gradual improvement of his symptoms during the hospitalization  |

Timeline patient 2:

| Date       | Significant event                                                                 |
|------------|----------------------------------------------------------------------------------|
| 11.1.2022  | A nasopharyngeal swab was performed due to symptom of chills, with a positive result for SARS-CoV-2 on a PCR assay. The symptoms resolved 2 days later |

Case reports

Case 1
A 42-year-old male presented to the emergency department with chest pain (8 January 2022). His medical history was remarkable for prior peri-myocarditis in 2008 without clear aetiology and without recurrence ever since, with no previous diagnosis of autoimmune disorders. The patient received three doses of BNT162b2 mRNA vaccines (third dose on 22 August 2021). He also had hyperlipidaemia treated with ezetimibe as sole chronic medication. Upon emergency department presentation, the patient describes several episodes of a retrosternal squeezing pain, each episode lasting for 3–4 h, without any precipitating or relieving factors. He also described decreased tolerance for exertion during the last three days. The patient denied dyspnoea, fever, cough, and further symptoms.

On arrival to the emergency department, the patient complains of ongoing pain that relieved during his stay there, physical examination revealed blood pressure of 131/84 mm/Hg, heart rate of 74 beats per minute, oxygen saturation of 97% while breathing ambient air, and body temperature of 36.7°C. Physical examination was unremarkable. A 12-lead electrocardiogram (ECG) showed sinus rhythm, ST-segment elevation in the inferior and posterior leads, and ST-segment depression in lead AVL (Figure 1). Upon arrival, high-sensitivity Troponin I level was 6309 ng/L (upper normal limit of 20 ng/L), the C-reactive protein level was 10.98 mg/L, the rest of the blood tests were unremarkable.

Given the patients’ complaints, his ECG and the bed side echocardiography that revealed overall preserved left ventricular ejection fraction with regional wall abnormalities of the inferior wall, urgent coronary angiography was performed, demonstrating non-significant coronary artery disease.

The patient was admitted to the intensive care unit with a diagnosis of suspected myocarditis, treatment with ibuprofen (800 mg, three times a day) and colchicine (0.5 mg twice a day) were started. A nasopharyngeal swab was performed upon admission to the intensive care

Continued
unit (8 January) with a positive result for SARS-CoV-2 on real-time reverse transcriptase–polymerase chain reaction assay. Omicron variant was later determined by genotyping.

Transthoracic echocardiography revealed involvement of the inferior wall. No pericardial effusion was observed.

Cardiac magnetic resonance imaging (MRI) was performed using a 1.5T scanner and standard scanning protocol. Both ventricles were normal in size and function (left ventricular ejection fraction = 58%, right ventricular ejection fraction = 52%) with no wall motion abnormality. Hyper-intense signal in the lateral and inferior wall segments on T2 sequence, consistent with oedema was demonstrated. Late gadolinium enhancement (LGE) obtained in the accepted cardiac planes (short-axis, four-chamber, three-chamber, and two-chamber) demonstrated extensive epicardial involvement (sparing the sub-endocardium) of the lateral wall, in a typical non-ischaemic pattern. LGE involvement was quantified as involving 22% of the left ventricular mass, using a dedicated platform (IntelliSpace Portal 11 Philips Healthcare) (Figure 2).

The patient was hemodynamically stable during the stay, without dyspnoea, but continued to complain of intermittent chest pain that re-lived by the end of his hospitalization. His troponin level increased to maximal level of 10 445 ng/L (on the third day of his hospital stay) and decreased steadily to 190 ng/L upon his discharge, five days after his hospital admission. The rest of his lab tests remained unremarkable. Throughout the hospital stay, no ventricular arrhythmias were recorded. The patient was discharged with recommendation to continue the treatment with colchicine and cardiologic follow-up.

Case 2
A 60-year-old physically active male, with past medical history of controlled asthma currently without the need for chronic therapy and without prior autoimmune disorders, had no chronic medications. He was vaccinated with three doses of BNT 162b2 mRNA COVID-19 vaccine (third dose on 30 August 2021). The patient was confirmed for COVID-19 with Omicron on the 11 January 2022. He have had chills for two days with no other symptoms. On the 21 January, while he was playing table tennis, he had witnessed syncope lasting up to 1 min. He denied any symptoms prior to the syncope including chest pain, palpitations, and dizziness. After he regained consciousness, he had palpitations for the first time in his life with general weakness. While still suffering from palpitations and weakness, he was transferred to the emergency department, where upon presentation he complained of chest pain. He quickly deteriorated and became confused with no pulse palpated and with monomorphic ventricular tachycardia of 250 beats per minute on the monitor. He had synchronized cardioversion with escape junctional rhythm of 40 per minute and after two more minutes sinus rhythm restored. Soon after the cardioversion, he felt well with no recurrence of palpitations, chest pain, or weakness during his hospital stay.

Physical examination after the cardioversion revealed blood pressure of 110/76 mm Hg, heart rate of 58 beats per minute, oxygen saturation of 99% while breathing ambient air. Physical examination was unremarkable. Five minutes after the cardioversion the 12-lead ECG showed sinus rhythm, ST-segment elevation in AVR, ST-segment depression in the inferior and lateral leads (Figure 3). Upon arrival, high-sensitivity Troponin I level was 53 ng/L (upper normal limit of 20 ng/L), with a maximal level of 4400 ng/L on his second test 8 h later, the C-reactive protein level was 5 mg/L (and stayed unchanged during his hospitalization), the rest of the blood tests were unremarkable. The patient was admitted to cardiac intensive unit, where he had no complaints. A nasopharyngeal swab was performed with a still positive result for SARS-CoV-2 of Omicron variant on real-time reverse transcriptase–polymerase chain reaction assay.

For the first day of his hospitalization, he had several non-sustained ventricular tachycardia of up to five beats. His echocardiography revealed preserved left ventricular ejection fraction of 50%, with posterior wall akinesis and inferior wall hypokinesis, with no pericardial effusion. Coronary angiography was performed demonstrating non-significant coronary artery disease and slight irregularities in the left anterior descending artery and the first diagonal artery.

Cardiac MRI was performed using a 3T scanner and standard scanning protocol. The left ventricle was normal in size with mild reduction in function (left ventricular ejection fraction = 51%). The right ventricle...
was normal in size and function (right ventricular ejection fraction = 48%) with no wall motion abnormality. LGE demonstrated extensive epicardial involvement (sparring the sub-endocardium) of the lateral wall and apex. LGE was calculated to involve 19% of the left ventricular mass. T1 mapping demonstrated increased native T1 values up to 1350–1440 ms (normal values in this 3T scanner are 1200 ± 50 ms) and an increased extracellular volume value of up to 37% (normal value—up to 28%) (Figure 4).

The patient has been haemodynamically stable during his stay, without chest pain, palpitations and dyspnoea during his hospitalization. After the first day of his hospitalization, he had no recurrences of arrhythmias recorded on continuous monitoring, treated only with bisoprolol 1.25 mg and without any treatment with anti-arrhythmic medications. He was discharged with wearable cardioverter-defibrillator until repeated cardiac MRI and arrhythmias specialist visit follow-up 3 months following hospital discharge for the decision regarding permanent implantable cardioverter-defibrillator (ICD). On April 2022, the patient had additional MRI with LGE involving 16% of the LV and consequently was recommended permanent ICD.

Discussion

To the best of our knowledge this is the first report of cases of myocarditis among COVID-19, Omicron confirmed patient, with malignant
Myocarditis associated with Omicron variant

Cardiac involvement in COVID-19 has been reported previously with conflicting data regarding its prevalence depending on the severity of the disease. Cardiac involvement in COVID-19 patients is well established, especially in hospitalized patients with prognostic value for these patients. Most of the previous reports addressed the cardiac involvement solely as troponin elevation. However, it was shown that most of these patients are likely to have ongoing inflammatory process within their myocardial tissue. Several possible mechanisms were suggested to explain the SARS-CoV2 myocarditis: (i) direct viral injury to the myocardial injury; (ii) CD8 T lymphocytes mediated cytotoxicity by migration to cardiomyocytes and induction of local inflammation; (iii) hyperactivation of the innate and adaptive autoimmune system as part of a systemic inflammation.

Omicron is a new variant of the SARS-CoV2 with numerous recognized mutations in the coding gene of the receptor binding domain and the N-terminal domain in the viral spike protein responsible for the efficient cell entry through the ACE2 receptor. Consequently, Omicron variant is estimated to be 2–3 times more transmissible compared to the Delta variant and thus explaining the quick spread and the peak number of daily new cases of new COVID-19 in most of western countries. This phenomenon is observed despite the increasing rate of vaccinated persons around the globe. Meanwhile, the published reports of the new variant severity from South Africa, where Omicron was first recognized, describe less severe clinical course with lower hospitalization rates by up to 50% compared with the delta variant. Other reports from the United Kingdom and Denmark report of similar hospitalization rate and disease severity caused by Omicron compared with previously encountered SARS-CoV2 variants. However, none of previous reports addressed the cardiovascular effect of Omicron variant and myocarditis specifically. The aforementioned cases suggest that the COVID-19 of Omicron variant may involve the heart, leading to myocarditis in particular, with further complications such as malignant arrhythmia with haemodynamic instability as observed in the second patient.

Limitations

Endomyocardial biopsy was not conducted as suggested traditionally for definitive myocarditis diagnoses despite its low sensitivity. However, we based our diagnosis on cardiac MRI which is the test of choice in most of myocarditis diagnosed cases of the overall population and those with COVID-19 in particular.

In conclusion, we believe that this report of myocarditis among Omicron COVID-19 patients, highlights the need to account for the possibility of this diagnosis in patients presenting with cardiac related symptoms such as angina, syncope and palpitations in the following period of the sharp rise in the COVID-19 cases. This is of importance especially in light of suggested less severe, flu-like, clinical course of the COVID-19 caused by Omicron variant.

Lead author biography

Boris Fishman is a second year cardiology fellow at the Leviev Heart institute, in Sheba Medical Center, Tel-Hashomer, Israel, where he also finished his residency in internal medicine. He received his medical degree from the Goldman School of Medicine, Ben Gurion University, Beer-Sheva, Israel, where he also completed his MPH degree. He has special interest in heart failure and cardiology of the older adult population.
Supplementary material

Supplementary material is available at European Heart Journal – Case Reports online.

Slide sets: A fully edited slide set detailing this case and suitable for local presentation is available online as Supplementary data.

Consent: The authors confirm patients’ consent for submission and publication of these case reports including images of their ECG and cardiac MRI in accordance with COPE guidelines.

Conflict of interest: None declared.

Funding: None declared.

Data availability
The data included in this manuscript is a case report rather than a database.

References
1. Hu B, Guo H, Zhou P, et al. Characteristics of SARS-CoV-2 and COVID-19. Not Rev Microbiol 2021;19:141–154.
2. Khaloo P, Shaqdan A, Ledesma PA, et al. Distinct etiologies of high-sensitivity troponin T elevation predict different mortality risks for patients hospitalized with COVID-19. Int J Cardiol 2022;351:118–125.
3. Lala A, Johnson KW, Januzzi JL, et al. Prevalence and impact of myocardial injury in patients hospitalized with COVID-19 infection. J Am Coll Cardiol 2020;76:533–546.
4. Bernal-Torres W, Herrera-Escandón A, Hurtado-Rivera M, et al. COVID-19 fulminant myocarditis: a case report. S Eur Heart J Case Rep 2020;4:1–6.
5. Fiore G, Savito F, Fragasso G, et al. Case report of cardiogenic shock in COVID-19 myocarditis: peculiarities on diagnosis, histology, and treatment. Eur Heart J Case Rep 2021;5.
6. Dyer O. COVID-19: omicron is causing more infections but fewer hospital admissions than delta. South African data show. BMJ 2021;3104.
7. Papageorgiou JM, Almroth H, Tornudd M, et al. Fulminant myocarditis in a COVID-19 positive patient treated with mechanical circulatory support – a case report. Eur Heart J Case Rep 2021;5.
8. Hachmann NP, Miller J, Collier AY, et al. Neutralization Escape by SARS-CoV-2, omicron subvariants BA.2,12,1, BA.4, and BA.5. N Eng J Med 2022;387:86–88.
9. Wolter N, Jassat W, Walaza S, et al. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. Lancet 2022;399:437–446.
10. del Rio C, Omer SB, Malani PN. Winter of omicron—the evolving COVID-19 pandemic. JAMA 2022;327:319–320.
11. Carretta DM, Silva AM, D’Agostino D, et al. Cardiac involvement in COVID-19 patients: a contemporary review. Infect Dis Rep 2021;13:494–517.
12. Daniels CJ, Rajpal S, Greenshields JT, et al. Prevalence of clinical and subclinical myocarditis in competitive athletes with recent SARS-CoV-2 infection: results from the big ten COVID-19 cardiac registry. JAMA Cardiol 2021;6:1078–1087.
13. Dagan N, Bara D, Balicer RD. Adverse effects after BNT162b2 vaccine and SARS-CoV-2 infection, according to age and sex. N Eng J Med 2021;385:2299–2299.
14. Witberg G, Bara D, Hoss S, et al. Myocarditis after COVID-19 vaccination in a large health care organization. N Eng J Med 2021;385:2132–2139.
15. Kleynhans J, Tempia S, Wolter N, et al. SARS-CoV-2 seroprevalence in a rural and urban household cohort during first and second waves of infections. South Africa July 2020-march 2021. Emerging Infect Dis. 2021;27:3020–3029.
16. Mahase E. COVID-19: hospital admission 50-70% less likely with omicron than delta, but transmission a major concern. BMJ 2021;375:n3151.
17. Ammirati E, Frigerio M, Adler ED, et al. Management of acute myocarditis and chronic inflammatory cardiomyopathy: an expert consensus document. Circ Heart Fail 2020;663–687.
18. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599–3726.